Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Lance B's : Its A Beautiful Thing -- Ignore unavailable to you. Want to Upgrade?

To: david simns who wrote (3465)	1/28/2000 2:29:00 PM
From: LANCE B	Read Replies (1) \| Respond to of 4792

BCAM-WELL I AM WRONG.guess you do not utilise silicon investor as well as you should i posted this stock at 1 p.m over on the golden thread.

To: david simns who wrote (3465)	1/28/2000 2:31:00 PM
From: LANCE B	Respond to of 4792

: $5 and Under : THE GOLDEN LISTS \| Previous \| Next \| Respond \| To: Jim Bishop (23045 ) From: LANCE B Friday, Jan 28 2000 12:28PM ET Reply # of 23141 BCAM-THIS IS BIG...STOCK ON THE VERGE OF A BREAKOUT...SMALL UPTICKS EVERYDAY AND EXCELLENT NEWS THAT NOBODY REALLY CAUGHT.. (COMTEX) B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRAT B: BCAM INTERNATIONAL ANNOUNCES ITS NEW CONSUMER SALES STRATEGY FOR DISTRIBUTING THE LUNGCHECK(R) CANCER SCREENING PROGRAM OVER THE Internet MELVILLE, N.Y., Jan 13, 2000 /PRNewswire via COMTEX/ -- BCAM International, Inc. (OTC Bulletin Board: BCAM) announced the following: On January 13, 2000, LungCheck Health, Inc. ("LungCheck"), a wholly owned subsidiary of BCAM International, Inc. announced its new plans to become the preeminent provider of pulmonary disease programs and information to consumers on the Internet. The Company plans to promote its proprietary quantitative sputum cytology test, LungCheck(R), directly on its own website (http://www.lungcheck.com) as well as through other leading web portals that service the healthcare consumer. The Company's innovative "e-health" strategy includes the utilization of a nationwide physician network through partnerships with leading disease management companies and world-renowned medical institutions. These partnerships will provide the necessary physician oversight for the ordering and reporting of LungCheck(R) test results and follow-up care for patients requesting the test in each state. LungCheck is a pulmonary pathology product and services company specializing in early lung disease screening and the assessment of lung health through the utilization of its proprietary quantitative sputum cytology test and program called LungCheck(R). The Company currently distributes its LungCheck(R) Sputum Cytology Test and Program through partnerships with leading providers of testing services to Fortune 500 Companies as part of their corporate wellness and/or screening programs. The Company also distributes its sputum test and program to large medical clinics where it has been successfully used as a biofeedback mechanism to aid in smoking cessation and as a monitoring